参考文献:1. Aapro M, Bernard-Marty C, Brain EG, et al. (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 22(2): 257-67 CrossRef 2. Barnadas A, Gil M, González S, et al. (2009) Exemestane as primary treatment of estrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 100(3): 442-49. Epub 2009 Jan 20 CrossRef 3. Bear HD (2010) Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Surg Oncol Clin N Am 19(3): 607-26 CrossRef 4. Brain EG, Mertens C, Girre V, et al. (2011) Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: a French Geriatric Oncology Group (GERICO) phase II multicentre trial. Crit Rev Oncol Hematol 80(1): 160-70 CrossRef 5. Chia YH, Ellis MJ, Ma CX (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer 103(6): 759-64. Epub 2010 Aug 10 CrossRef 6. Dixon JM, Renshaw L, Macaskill EJ, et al. (2009) Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 113(1): 145-51. Epub 2008 Feb 9 CrossRef 7. Ellis MJ, Miller WR, Tao Y et al. (2009) Aromatase expression and out-comes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat 116(2): 371-78. Epub 2008 Oct 22 CrossRef 8. Ellis MJ, Tao Y, Luo J, et al. (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100(19): 1380-388. Epub 2008 Sep 23 CrossRef 9. Galimberti V, Botteri E, Chifu C, et al. (2011) Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat DOI:10.1007/s10549-011-1486-2-Published on line 10. Lee SJ, Lindquist K, Segal MR, et al. (2006) Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295(7): 801-08 CrossRef 11. Luciani A, Ascione G, Bertuzzi C, et al. (2010) Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. JCO 28(12): 2046-050 CrossRef 12. Mello-Grand M, Singh V, Ghimenti C, et al. (2010) Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast 121(2): 399-11. Epub 2010 Apr 29 13. Miller WR (2009) Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 118(4-): 273-76 14. Molina-Garrido MJ, Guillen-Ponce C (2011) Comparison of two frailty screening tools in older women with early breast cancer. Crit Rev Oncol Hematol 79: 51-4 CrossRef 15. Overcash JA, Beckstead J, Extermann M, Cobb S (2005) The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol 54: 129-36 CrossRef 16. Seo JH, Kim YH, Kim JS (2009) Meta-analysis of preoperative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother Pharmacol 63(2): 261-66. Epub 2008 Mar 26 CrossRef 17. Soubeyran P, Bellera C, Goyard J, et al. (2011) Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project. J Clin Oncol 29 (suppl; abstr 9001) 18. Veronesi U, Marubini E, Mariani L, et al. (2001) Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12(7): 997-003 CrossRef 19. Viehl CT, Langer I, Guller U, et al. (2011) Prognostic impact and therapeutic implications of sentinel lymph node micrometastases in early-stage breast cancer patients. J Surg Oncol 103(6): 531-33 CrossRef